

PRESS CLIPPING SHEET

| | |
|----------------------|---|
| PUBLICATION: | Egyptian Mail |
| DATE: | 31-May-2016 |
| COUNTRY: | Egypt |
| CIRCULATION: | 60,000 |
| TITLE : | AstraZeneca: What science can do |
| PAGE: | Back Page |
| ARTICLE TYPE: | AD |
| REPORTER: | ----- |

PRESS CLIPPING SHEET


What science can do



AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

At AstraZeneca, our purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve this is to put science at the centre of everything we do. It is this commitment that drives our ability to discover, develop and deliver the advancements the world needs in complex and difficult diseases like cancer, heart disease, diabetes, COPD and asthma.

For more information please visit:
www.astrazeneca.com



Biologics in the treatment of asthma
Eosinophils are known to infiltrate the airways of some asthma patients and cause airway inflammation. AstraZeneca is developing a biologic that binds to the surface of eosinophils and recruits natural killer cells to remove them from circulation.

AZE-300-365-ADN-0516-0016